Biostar Pharmaceuticals Expects Qualified Opinion on FY2025 Audit

Bulletin Express
03/25

Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR) announced that its external auditor anticipates issuing a qualified opinion on the consolidated financial statements for the year ended 31 December 2025.

The board is currently engaging with the auditor to resolve the matters leading to the expected qualification. Detailed information will be provided in the forthcoming FY2025 annual results release.

The company advised shareholders and potential investors to exercise caution when trading its shares.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10